Session Details
[3MS-14]【J】Quantitative Biology of Heterogeneity Regulation
Fri. Nov 29, 2024 3:10 PM - 4:30 PM JST
Fri. Nov 29, 2024 6:10 AM - 7:30 AM UTC
Fri. Nov 29, 2024 6:10 AM - 7:30 AM UTC
Room 14(Marine Messe Fukuoka Hall B, 2F Meeting Room 1-1)
Organizer: Jun Nakayama (Osaka International Cancer Institute), Kenichi Miyata (Cancer Institute, Japanese Foundation for Cancer Research)
Recent breakthroughs in omics and single-cell analysis reveals cellular heterogeneity and gene-expressional heterogeneity in various situation, including development, aging, and cancer. In this symposium, we will take a "quantitative" viewpoint of heterogeneity and approach the essence of the mechanism in heterogeneity. The regulation and dynamics of heterogeneity will be discussed from broad-based field including quantitative analysis of heterogeneity, mathematical model, and in vivo live imaging.
[3MS-14-01]Quantitative analysis of heterogeneity with single-cell level by VARIED method
○Jun Nakayama1,2, Yusuke Yamamoto2 (1. Dept. of Oncogenesis and Growth Regulation, Res. Inst.,Osaka Intl. Cancer Inst., 2. Lab. of Integr. Oncol., Natl. Cancer Ctr. Res. Inst.)
[3MS-14-02]Elucidation of the mechanisms underlying muscle integrity supported by heterogeneity of mesenchymal progenitors
○Madoka Uezumi1, Shinichiro Hayashi2, Satoru Noguchi2, Ichizo Nishino2, Tamaki Kurosawa3, Takeshi Nikawa4, Akiyoshi Uezumi1 (1. Div. of Cell Hetero., Med. Inst. of Bioreg., Kyushu Univ., 2. Dept. of Neuromuscul. Res., Natl. Inst. of Neurosci., NCNP, 3. Dept. of Vet. Pharmacol., Grad School of Agric.and Life Sci., Tokyo Univ., 4. Dept. of Nutr. Physiol., Inst. of Biomed. Sci., Grad school of Tokushima Univ.)
[3MS-14-03(3P-116)]Unveiling the molecular basis of irreversible epigenetic heterogeneity
○Takuya Kajitani1, Hiroaki Kato2, Hiroshi Kimura3, Yasuyuki Ohkawa4, Chikashi Obuse5, Damien Hermand6, John Lis7, Yota Murakami8 (1. Univ. of Fukui, 2. Shimane Univ., 3. Tokyo Tech, 4. Kyushu Univ., 5. Osaka Univ., 6. Univ of Namur, 7. Cornell Univ., 8. Hokkaido Univ.)
[3MS-14-04]Higher order structure of chromatin regulates chromatin stiffness
○Shiori Iida1,2, Masahito Tanaka3, Sachiko Tamura1, Yuta Shimamoto2,3, Kazuhiro Maeshima1,2 (1. Genome Dynamics Lab., NIG, 2. SOKENDAI, 3. Physics and Cell Biology Lab., NIG)
[3MS-14-05(3P-838)]Tumor heterogeneity of branched-chain amino acid and the activated metabolism regulates the aggressive nature in human triple-negative breast cancer
○Kenkyo Matsuura1, Itsuki Kuroda1,2, Ririko Shinonaga1,2, Mizuki Yamamoto3, Jun-ichiro Inoue3, Hiromi Imamura4, Ayuna Hattori1, Takahiro Ito1 (1. Inst. for Life and Med. Sci., Kyoto Univ., 2. Grad. Sch. of Pharm. Sci., Kyoto Univ., 3. Inst. for Med. Sci., Univ. of Tokyo, 4. Grad. Sch. of Biostudies, Kyoto Univ.)
[3MS-14-06(3P-819)]Identification of cell competition markers
○Eilma Akter1, Olivia Marchia Kusuma1, Takahiro Kuchimaru3, Shunsuke Kon2 (1. Tokyo Univ. of Sci., Grad. Sch. of Bio. Sci. , 2. Tokyo Univ. of Sci., Res. Inst. for Bio. Sci., 3. Jichi Med. Univ. Ctr. for Mol. Med.)
[3MS-14-07(3P-821)]Quantitative live imaging of ERK MAPK and AMPK activity in patient-derived pancreatic cancer organoids
○Toru Hiratsuka1, Shoko Tsukamoto2, Houssam Alkoussa2, Akihito Machinaga3, Nobuyuki Kakiuchi4, Seishi Ogawa5,6,7, Hiroshi Seno4, Shigeki Higashiyama1, Michiyuki Matsuda2 (1. Osaka International Cancer Institute, 2. Lab. of Cell Cycle Regulation, Kyoto Univ., 3. Discovery, Med. Creation, OBG, Eisai Co., Ltd,, 4. Dept. of Gastroenterol and Hepatol., Kyoto Univ., 5. Dept. of Pathol. and Tumor Biol., Kyoto Univ., 6. WPI-ASHBi, Kyoto Univ., 7. Dept. Med., Karolinska Inst., Stockholm, Sweden)
[3MS-14-08]Analysis of epigenomic heterogeneity in patient-derived organoids of pancreatic cancer
○Kenichi Miyata1,2, Takaaki Furukawa1,3, Yuxiao Yang1, Chikako Shibata1, Tetsuo Noda2,4, Naoki Sasahira3, Reo Maruyama1,2 (1. Project for Cancer Epigenomics, Cancer Institute, JFCR, 2. NEXT-Ganken, JFCR, 3. Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of JFCR, 4. Cancer Institute, JFCR)